{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T23:44:23Z","timestamp":1782690263212,"version":"3.54.5"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lung cancer is still among the most malignant cancers, with immunotherapy becoming a ground-breaking treatment option. The ICIs and other immunotherapeutic drugs usually cause severe immune-related adverse effects curtailing their therapeutic efficacy. Meeting this challenge, Nano medicine-based drug delivery systems have gained considerable interest as they hold the promise of increasing therapeutic benefits at the same time as reducing toxicity. This chapter discusses the complex balance between the effectiveness and toxicity of lung cancer immunotherapy, underlining the application of nanotechnology in maximizing drug delivery. Nano carriers like liposomes, polymeric nanoparticles, dendrites, and lipid-based systems have demonstrated the capacity to augment the bioavailability of pharmaceuticals, facilitating tumour-specific environments, and alleviating systemic side effects. Other options suggest that stimuli-responsive and ligand-functionalized Nano platforms can provide spatial control over the immune response by enhancing infiltration to the tumour site while reducing toxicity to healthy organs. On the battlegrounds of nanomedicine, inhibiting resistance mechanisms consolidated with immune checkpoint inhibitors and conventional chemotherapeutics has conferred better therapeutic responses upon the patient. Its stability, bio-distribution, and regulatory pathway concerns still challenge clinical translation. The chapter discusses recent advances in preclinical and clinical testing and describes the development of Nano medicine-based regulatory T-cell-directed immunotherapy for lung and lung-associated cancers. The problems concerning both toxicity and the application of nanotechnology for targeting therapy will open new avenues toward developing safer and more effective antitumor immunotherapeutic regimes for lung cancer.<\/jats:p>","DOI":"10.1186\/s43046-026-00358-7","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T23:02:56Z","timestamp":1782687776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Navigating toxicity in lung cancer immunotherapy: challenges and advances in Nano medicine drug delivery"],"prefix":"10.1186","volume":"38","author":[{"given":"Rishab","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananda Kumar","family":"Chettupalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarad Pawar Naik","family":"Bukke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya","family":"Sankarapandian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ungo-Kore Hussain","family":"Yahaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"358_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri A, Maji A, Potdar PD, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22:40. https:\/\/doi.org\/10.1186\/s12943-023-01740-y.","journal-title":"Mol Cancer"},{"issue":"1","key":"358_CR2","doi-asserted-by":"publisher","first-page":"e13122","DOI":"10.15252\/emmm.202013122","volume":"13","author":"J Ko","year":"2021","unstructured":"Ko J, Winslow MM, Sage J. Mechanisms of small cell lung cancer metastasis. EMBO Mol Med. 2021;13(1):e13122. https:\/\/doi.org\/10.15252\/emmm.202013122.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"358_CR3","doi-asserted-by":"publisher","first-page":"2169531","DOI":"10.1080\/21645515.2023.2169531","volume":"19","author":"Y Lu","year":"2023","unstructured":"Lu Y, Zhang X, Ning J, Zhang M. Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis. Hum vaccines immunotherapeutics. 2023;19(1):2169531. https:\/\/doi.org\/10.1080\/21645515.2023.2169531.","journal-title":"Hum vaccines immunotherapeutics"},{"issue":"7","key":"358_CR4","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, Mccleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, Mccune S, Mekhail T, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924\u201337. https:\/\/doi.org\/10.1016\/S1470-2045(19)30167-6.","journal-title":"Lancet Oncol"},{"key":"358_CR5","doi-asserted-by":"publisher","first-page":"823618","DOI":"10.3389\/fimmu.2022.823618","volume":"13","author":"H Mamdani","year":"2022","unstructured":"Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. Immunotherapy in Lung Cancer: Current Landscape and Future Directions. Front Immunol. 2022;13:823618. https:\/\/doi.org\/10.3389\/fimmu.2022.823618.","journal-title":"Front Immunol"},{"key":"358_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41422-019-0184-1","volume":"29","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Du X, Liu M, Tang F, Zhang P, Ai C, et al. Hijacking Antibody-Induced CTLA-4 Lysosomal Degradation for Safer and More Effective Cancer Immunotherapy. Cell Res. 2019;29:609\u201327. https:\/\/doi.org\/10.1038\/s41422-019-0184-1.","journal-title":"Cell Res"},{"issue":"14","key":"358_CR7","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients With NSCLC. N Engl J Med. 2020;383(14):1328\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1917346.","journal-title":"N Engl J Med"},{"issue":"1","key":"358_CR8","doi-asserted-by":"publisher","first-page":"e1654","DOI":"10.1002\/wnan.1654","volume":"13","author":"W Wang","year":"2021","unstructured":"Wang W, Hao Y, Liu Y, Li R, Huang DB, Pan YY. Nanomedicine in lung cancer: Current states of overcoming drug resistance and improving cancer immunotherapy. Wiley Interdisciplinary Reviews: Nanomed Nanobiotechnol. 2021;13(1):e1654. https:\/\/doi.org\/10.1002\/wnan.1654.","journal-title":"Wiley Interdisciplinary Reviews: Nanomed Nanobiotechnol"},{"key":"358_CR9","doi-asserted-by":"publisher","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","volume":"14","author":"Q Yin","year":"2023","unstructured":"Yin Q, Wu L, Han L, Zheng X, Tong R, Li L, Bai L, Bian Y. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975. https:\/\/doi.org\/10.3389\/fimmu.2023.1167975.","journal-title":"Front Immunol"},{"key":"358_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1166\/sam.2023.4438","volume":"15","author":"MZ Ahmad","year":"2023","unstructured":"Ahmad MZ, Ahmad J, Umar A, Abdel-Wahab BA, Lahiq AA, Khan NH, Pathak K, Rizwanullah M, Warsi MH, Saikia R, Pathak MP. Nanomaterials in cancer immunotherapy: A spotlight on breast cancer. Sci Adv Mater. 2023;15:285\u2013318.","journal-title":"Sci Adv Mater"},{"issue":"2","key":"358_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368. https:\/\/doi.org\/10.1056\/NEJMra1703481.","journal-title":"N Engl J Med"},{"issue":"7","key":"358_CR12","doi-asserted-by":"publisher","first-page":"6805","DOI":"10.3390\/curroncol30070498","volume":"30","author":"YS Teng","year":"2023","unstructured":"Teng YS, Yu S. Molecular mechanisms of cutaneous immune-related adverse events (irAEs) induced by immune checkpoint inhibitors. Curr Oncol. 2023;30(7):6805\u201319. https:\/\/doi.org\/10.3390\/curroncol30070498.","journal-title":"Curr Oncol"},{"key":"358_CR13","doi-asserted-by":"publisher","first-page":"106221","DOI":"10.1016\/j.intimp.2020.106221","volume":"80","author":"A Hosseini","year":"2020","unstructured":"Hosseini A, Gharibi T, Marofi F, Babaloo Z, Baradaran B. CTLA-4: From mechanism to autoimmune therapy. Int Immunopharmacol. 2020;80:106221. https:\/\/doi.org\/10.1016\/j.intimp.2020.106221.","journal-title":"Int Immunopharmacol"},{"key":"358_CR14","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/cancers13061440","volume":"13","author":"N Sobhani","year":"2021","unstructured":"Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D, Roudi R, Li Y. CTLA-4 in Regulatory T Cells for Cancer Immunotherapy. Cancers. 2021;13:1440. https:\/\/doi.org\/10.3390\/cancers13061440.","journal-title":"Cancers"},{"key":"358_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.tips.2019.11.003","volume":"41","author":"Y Liu","year":"2020","unstructured":"Liu Y, Zheng P. Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy. Trends Pharmacol Sci. 2020;41:4\u201312. https:\/\/doi.org\/10.1016\/j.tips.2019.11.003.","journal-title":"Trends Pharmacol Sci"},{"key":"358_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18:153\u201367. https:\/\/doi.org\/10.1038\/nri.2017.108.","journal-title":"Nat Rev Immunol"},{"key":"358_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13045-021-01161-8","volume":"14","author":"W Qian","year":"2021","unstructured":"Qian W, Zhao M, Wang R, Li H. Fibrinogen-like protein 1 (FGL1): The next immune checkpoint target. J Hematol Oncol. 2021;14:147. https:\/\/doi.org\/10.1186\/s13045-021-01161-8.","journal-title":"J Hematol Oncol"},{"key":"358_CR18","doi-asserted-by":"publisher","first-page":"956090","DOI":"10.3389\/fimmu.2022.956090","volume":"13","author":"JL Huo","year":"2022","unstructured":"Huo JL, Wang YT, Fu WJ, Lu N, Liu ZS. The promising immune checkpoint LAG-3 in cancer immunotherapy: From basic research to clinical application. Front Immunol. 2022;13:956090. https:\/\/doi.org\/10.3389\/fimmu.2022.956090.","journal-title":"Front Immunol"},{"key":"358_CR19","doi-asserted-by":"publisher","first-page":"823618","DOI":"10.3389\/fimmu.2022.823618","volume":"13","author":"H Mamdani","year":"2022","unstructured":"Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. Immunotherapy in lung cancer: current landscape and future directions. Front Immunol. 2022;13:823618. https:\/\/doi.org\/10.3389\/fimmu.2022.823618.","journal-title":"Front Immunol"},{"issue":"14","key":"358_CR20","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients With NSCLC. N Engl J Med. 2020;383(14):1328\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1917346.","journal-title":"N Engl J Med"},{"key":"358_CR21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.lungcan.2019.07.004","volume":"135","author":"K Nosaki","year":"2019","unstructured":"Nosaki K, Saka H, Hosomi Y, Baas P, de Castro G Jr., Reck M, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Elderly Patients With PD-L1-Positive Advanced Non-Small-Cell Lung Cancer: Pooled Analysis From the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 Studies. Lung Cancer. 2019;135:188\u201395. https:\/\/doi.org\/10.1016\/j.lungcan.2019.07.004.","journal-title":"Lung Cancer"},{"issue":"19","key":"358_CR22","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1002\/cncr.33083","volume":"126","author":"GA Durm","year":"2020","unstructured":"Durm GA, Jabbour SK, Althouse SK, Liu Z, Sadiq AA, Zon RT, et al. A Phase 2 Trial of Consolidation Pembrolizumab Following Concurrent Chemoradiation for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN 14\u2013179. Cancer. 2020;126(19):4353\u201361. https:\/\/doi.org\/10.1002\/cncr.33083.","journal-title":"Cancer"},{"issue":"21","key":"358_CR23","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381(21):2020\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1910231.","journal-title":"N Engl J Med"},{"issue":"10","key":"358_CR24","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of Tumour Mutational Burden With Outcomes in Patients With Advanced Solid Tumours Treated With Pembrolizumab: Prospective Biomarker Analysis of the Multicohort, Open-Label, Phase 2 KEYNOTE-158 Study. Lancet Oncol. 2020;21(10):1353\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30445-9.","journal-title":"Lancet Oncol"},{"issue":"21","key":"358_CR25","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","volume":"38","author":"CM Rudin","year":"2020","unstructured":"Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csoszi T, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020;38(21):2369\u201379. https:\/\/doi.org\/10.1200\/JCO.20.00793.","journal-title":"J Clin Oncol"},{"issue":"1","key":"358_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10238-025-01892-9","volume":"26","author":"R Das","year":"2025","unstructured":"Das R, Deb S, Suresh PK. TMB as a predictive biomarker for ICI response in TNBC: current evidence and future directions for augmented anti-tumor responses. Clin Exp Med. 2025;26(1):25. https:\/\/doi.org\/10.1007\/s10238-025-01892-9.","journal-title":"Clin Exp Med"},{"issue":"16","key":"358_CR27","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1097\/CM9.0000000000003703","volume":"138","author":"Y Peng","year":"2025","unstructured":"Peng Y, Yu M, Li B, Zhang S, Cheng J, Wu F, Du S, Miao J, Hu B, Olkhovsky IA, Li S. Advances in nanocarrier-mediated cancer therapy: Progress in immunotherapy, chemotherapy, and radiotherapy. Chin Med J (Engl). 2025;138(16):1927\u201344. https:\/\/doi.org\/10.1097\/CM9.0000000000003703.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"358_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023;8(1):9. https:\/\/doi.org\/10.1038\/s41392-022-01270-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"358_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12935-023-02990-y","volume":"23","author":"M Araghi","year":"2023","unstructured":"Araghi M, Mannani R, Heidarnejad maleki A, Hamidi A, Rostami S, Safa SH, Faramarzi F, Khorasani S, Alimohammadi M, Tahmasebi S, Akhavan-Sigari R. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int. 2023;23(1):162. https:\/\/doi.org\/10.1186\/s12935-023-02990-y.","journal-title":"Cancer Cell Int"},{"key":"358_CR30","doi-asserted-by":"publisher","first-page":"12113","DOI":"10.2147\/OTT.S276150","volume":"13","author":"W Tian","year":"2020","unstructured":"Tian W, Cao C, Shu L, Wu F. Anti-angiogenic therapy in the treatment of non-small cell lung cancer. Onco Targets Ther. 2020;13:12113. https:\/\/doi.org\/10.2147\/OTT.S276150.","journal-title":"Onco Targets Ther"},{"issue":"23","key":"358_CR31","first-page":"10363","volume":"23","author":"L Wang","year":"2019","unstructured":"Wang L, Zhang L, Wang L, Zhu L, Ma X. Influence of miR-199a on rats with non-small cell lung cancer via regulating the HIF-1alpha\/VEGF signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(23):10363\u20139. https:\/\/www.europeanreview.org\/wp\/wp-content\/uploads\/10363-10369.pdf.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"358_CR32","doi-asserted-by":"publisher","first-page":"S894","DOI":"10.1016\/j.annonc.2020.08.1730","volume":"31","author":"M Reck","year":"2020","unstructured":"Reck M, Spira A, Besse B, Wolf J, Skoulidis F, Borghaei H, et al. 1416TiP CodeBreak 200: a phase III multicenter study of sotorasib (AMG 510), a KRAS (G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p. G12C mutation. Ann Oncol. 2020;31:S894\u20135. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.1730.","journal-title":"Ann Oncol"},{"key":"358_CR33","doi-asserted-by":"publisher","first-page":"S812","DOI":"10.1016\/j.annonc.2020.08.1571","volume":"31","author":"D Hong","year":"2020","unstructured":"Hong D, Bang Y, Barlesi F, Durm G, Falchook G, Govindan R, et al. 1257O Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib). Ann Oncol. 2020;31:S812. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.1571.","journal-title":"Ann Oncol"},{"issue":"13","key":"358_CR34","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS(G12C) Inhibition with sotorasib in advanced Solid tumors. N Engl J Med. 2020;383(13):1207\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1917239.","journal-title":"N Engl J Med"},{"issue":"3","key":"358_CR35","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","volume":"40","author":"MZ Wojtukiewicz","year":"2021","unstructured":"Wojtukiewicz MZ, Rek MM, Karpowicz K, G\u00f3rska M, Polity\u0144ska B, Wojtukiewicz AM, Moniuszko M, Radziwon P, Tucker SC, Honn KV. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev. 2021;40(3):949\u201382. https:\/\/doi.org\/10.1007\/s10555-021-09976-0.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"358_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10238-025-01892-9","volume":"26","author":"R Das","year":"2025","unstructured":"Das R, Deb S, Suresh PK. TMB as a predictive biomarker for ICI response in TNBC: current evidence and future directions for augmented anti-tumor responses. Clin Exp Med. 2025;26(1):25. https:\/\/doi.org\/10.1007\/s10238-025-01892-9.","journal-title":"Clin Exp Med"},{"issue":"4","key":"358_CR37","doi-asserted-by":"publisher","first-page":"211991","DOI":"10.1098\/rsos.211991","volume":"9","author":"TH Tran","year":"2022","unstructured":"Tran TH, Phuong Tran TT. Targeting the PD-1\/PD-L1 axis for cancer treatment: a review on nanotechnology. R Soc Open Sci. 2022;9(4):211991. https:\/\/doi.org\/10.1098\/rsos.211991.","journal-title":"R Soc Open Sci"},{"issue":"2","key":"358_CR38","doi-asserted-by":"publisher","first-page":"e1590","DOI":"10.1002\/wnan.1590","volume":"12","author":"Z Yang","year":"2020","unstructured":"Yang Z, Ma Y, Zhao H, Yuan Y, Kim BY. Nanotechnology platforms for cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020;12(2):e1590. https:\/\/doi.org\/10.1002\/wnan.1590.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"1","key":"358_CR39","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s13287-022-03212-4","volume":"13","author":"E Ghasempour","year":"2022","unstructured":"Ghasempour E, Hesami S, Movahed E, Doroudian M. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy in the brain tumors. Stem Cell Res Ther. 2022;13(1):527\u2013612. https:\/\/doi.org\/10.1186\/s13287-022-03212-4.","journal-title":"Stem Cell Res Ther"},{"key":"358_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/9624532","volume":"2020","author":"MA Buabeid","year":"2020","unstructured":"Buabeid MA, Arafa E-SA, Murtaza G. Emerging prospects for nanoparticle-enabled cancer immunotherapy. J Immunol Res. 2020;2020:1\u201311. https:\/\/doi.org\/10.1155\/2020\/9624532.","journal-title":"J Immunol Res"},{"issue":"1","key":"358_CR41","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12951-021-00975-5","volume":"19","author":"Z Wang","year":"2021","unstructured":"Wang Z, Chen L, Ma Y, Li X, Hu A, Wang H, et al. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal. J Nanobiotechnol. 2021;19(1):243\u2013316. https:\/\/doi.org\/10.1186\/s12951-021-00975-5.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"358_CR42","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12951-022-01692-3","volume":"20","author":"Z Chen","year":"2022","unstructured":"Chen Z, Yue Z, Yang K, Li S. Nanomaterials: Small particles show huge possibilities for cancer immunotherapy. J Nanobiotechnol. 2022;20(1):484\u2013538. https:\/\/doi.org\/10.1186\/s12951-022-01692-3.","journal-title":"J Nanobiotechnol"},{"issue":"12","key":"358_CR43","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi L, Humeau J, Buqu\u00e9 A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat reviews Clin Oncol. 2020;17(12):725\u201341. https:\/\/doi.org\/10.1038\/s41571-020-0413-z.","journal-title":"Nat reviews Clin Oncol"},{"issue":"7","key":"358_CR44","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1021\/acsbiomaterials.0c00439","volume":"6","author":"S Srinivasan","year":"2020","unstructured":"Srinivasan S, Babensee JE. Controlled delivery of immunomodulators from a biomaterial scaffold niche to induce a tolerogenic phenotype in human dendritic cells. ACS biomaterials Sci Eng. 2020;6(7):4062\u201376. https:\/\/doi.org\/10.1021\/acsbiomaterials.0c00439.","journal-title":"ACS biomaterials Sci Eng"},{"key":"358_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-020-02838-4","volume":"37","author":"C Li","year":"2020","unstructured":"Li C, Han X. Melanoma cancer immunotherapy using PD-L1 siRNA and imatinib promotes cancer-immunity cycle. Pharm Res. 2020;37:1\u20130. https:\/\/doi.org\/10.1007\/s11095-020-02838-4.","journal-title":"Pharm Res"},{"issue":"8","key":"358_CR46","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1021\/acs.biomac.1c00669","volume":"22","author":"L Zhang","year":"2021","unstructured":"Zhang L, Jin D, Stenzel MH. Polymer-functionalized upconversion nanoparticles for light\/imaging-guided drug delivery. Biomacromolecules. 2021;22(8):3168\u2013201. https:\/\/doi.org\/10.1021\/acs.biomac.1c00669.","journal-title":"Biomacromolecules"},{"issue":"22","key":"358_CR47","doi-asserted-by":"publisher","first-page":"6485","DOI":"10.7150\/thno.34429","volume":"9","author":"CG Da Silva","year":"2019","unstructured":"Da Silva CG, Camps MG, Li TM, Zerrillo L, L\u00f6wik CW, Ossendorp F, Cruz LJ. Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles. Theranostics. 2019;9(22):6485. https:\/\/doi.org\/10.7150\/thno.34429.","journal-title":"Theranostics"},{"issue":"1","key":"358_CR48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s42003-022-03103-7","volume":"5","author":"IM Meraz","year":"2022","unstructured":"Meraz IM, Majidi M, Shao R, Meng F, Ha MJ, Shpall E, et al. TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS\/LKB1 mutant NSCLC in humanized mouse model. Commun Biol. 2022;5(1):167\u2013213. https:\/\/doi.org\/10.1038\/s42003-022-03103-7.","journal-title":"Commun Biol"},{"issue":"6","key":"358_CR49","doi-asserted-by":"publisher","first-page":"7200","DOI":"10.1021\/acsnano.0c02207","volume":"14","author":"JL Perry","year":"2020","unstructured":"Perry JL, Tian S, Sengottuvel N, Harrison EB, Gorentla BK, Kapadia CH, et al. Pulmonary delivery of nanoparticle-bound toll-like receptor 9 agonist for the treatment of metastatic lung cancer. ACS Nano. 2020;14(6):7200\u201315. https:\/\/doi.org\/10.1021\/acsnano.0c02207.","journal-title":"ACS Nano"},{"issue":"6","key":"358_CR50","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1021\/acs.nanolett.8b00689","volume":"18","author":"NN Parayath","year":"2018","unstructured":"Parayath NN, Parikh A, Amiji MM. Repolarization of tumor-associated macrophages in a genetically engineered nonsmall cell lung cancer model by intraperitoneal administration of hyaluronic acid-based nanoparticles encapsulating microRNA-125b. Nano Lett. 2018;18(6):3571\u20139. https:\/\/doi.org\/10.1021\/acs.nanolett.8b00689.","journal-title":"Nano Lett"},{"issue":"20","key":"358_CR51","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.1039\/D0BM01191F","volume":"8","author":"T Yang","year":"2020","unstructured":"Yang T, Yu S, Liu L, Sun Y, Lan Y, Ma X, et al. Dual polymeric prodrug co-assembled nanoparticles with precise ratiometric co-delivery of cisplatin and metformin for lung cancer chemoimmunotherapy. Biomaterials Sci. 2020;8(20):5698\u2013714. https:\/\/doi.org\/10.1039\/D0BM01191F.","journal-title":"Biomaterials Sci"},{"issue":"1","key":"358_CR52","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s40820-021-00630-6","volume":"13","author":"S Rawal","year":"2021","unstructured":"Rawal S, Patel M. Bio-nanocarriers for lung cancer management: Befriending the barriers. Nano-Micro Lett. 2021;13(1):142\u201354. https:\/\/doi.org\/10.1007\/s40820-021-00630-6.","journal-title":"Nano-Micro Lett"},{"key":"358_CR53","doi-asserted-by":"publisher","unstructured":"Doroudian M, Azhdari MH, Goodarzi N, O\u2019Sullivan D, Donnelly SC. Smart nanotherapeutics and lung cancer. Pharmaceutics. 2021;13(11):1972. https:\/\/doi.org\/10.3390\/pharmaceutics13111972.","DOI":"10.3390\/pharmaceutics13111972"},{"issue":"1","key":"358_CR54","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1021\/acsomega.2c04078","volume":"8","author":"A Sharma","year":"2022","unstructured":"Sharma A, Shambhwani D, Pandey S, Singh J, Lalhlenmawia H, Kumarasamy M, Singh SK, Chellappan DK, Gupta G, Prasher P, Dua K. Advances in lung cancer treatment using nanomedicines. ACS omega. 2022;8(1):10\u201341. https:\/\/doi.org\/10.1021\/acsomega.2c04078.","journal-title":"ACS omega"},{"key":"358_CR55","doi-asserted-by":"publisher","first-page":"687399","DOI":"10.3389\/fphar.2021.687399","volume":"12","author":"JS He","year":"2021","unstructured":"He JS, Liu SJ, Zhang YR, Chu XD, Lin ZB, Zhao Z, Qiu SH, Guo YG, Ding H, Pan YL, Pan JH. The application of and strategy for gold nanoparticles in cancer immunotherapy. Front Pharmacol. 2021;12:687399. https:\/\/doi.org\/10.3389\/fphar.2021.687399.","journal-title":"Front Pharmacol"},{"issue":"11","key":"358_CR56","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.3390\/pharmaceutics14112463","volume":"14","author":"A Ahmad","year":"2022","unstructured":"Ahmad A, Imran M, Sharma N. Precision nanotoxicology in drug development: current trends and challenges in safety and toxicity implications of customized multifunctional nanocarriers for drug-delivery applications. Pharmaceutics. 2022;14(11):2463. https:\/\/doi.org\/10.3390\/pharmaceutics14112463.","journal-title":"Pharmaceutics"},{"key":"358_CR57","doi-asserted-by":"publisher","unstructured":"Karati D, Mukherjee S, Prajapati B, Bose A, Paul S, Elossaily GM, Roy S. A review on lipid-polymer hybrid nanocarriers in cancer. J Drug Deliv Sci Technol. 2024:105827. https:\/\/doi.org\/10.1016\/j.jddst.2024.105827Getrightsandcontent.","DOI":"10.1016\/j.jddst.2024.105827Getrightsandcontent"},{"key":"358_CR58","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.2147\/IJN.S376216","volume":"17","author":"Z Jiang","year":"2022","unstructured":"Jiang Z, Zhang W, Zhang J, Liu T, Xing J, Zhang H, Tang D. Nanomaterial-Based Drug Delivery Systems: A New Weapon for Cancer Immunotherapy. Int J Nanomed. 2022;17:4677\u201396. https:\/\/doi.org\/10.2147\/IJN.S376216.","journal-title":"Int J Nanomed"},{"issue":"9","key":"358_CR59","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3390\/cancers17091408","volume":"17","author":"V Mc Neil","year":"2025","unstructured":"Mc Neil V, Lee SW. Advancing cancer treatment: A review of immune checkpoint inhibitors and combination strategies. Cancers. 2025;17(9):1408.","journal-title":"Cancers"},{"issue":"22","key":"358_CR60","doi-asserted-by":"publisher","first-page":"7086","DOI":"10.1039\/d5na00390c","volume":"7","author":"J Bhatt","year":"2025","unstructured":"Bhatt J, Jain S, Gupta S, Bhatia DD. Nanomedicine revolutionizing cancer immunotherapy: recent advancements in nanotechnological strategies and applications. Nanoscale Adv. 2025;7(22):7086\u2013108. https:\/\/doi.org\/10.1039\/d5na00390c.","journal-title":"Nanoscale Adv"},{"key":"358_CR61","doi-asserted-by":"publisher","unstructured":"Jayaraj S, Jayaprakash N, Devaraji M, Murugavel S, Robinson AX, Murugesan L. Nanocarrier-Based Strategies for Advanced Cancer Drug Delivery and Therapeutics: Design Principles, Biological Interactions, and Clinical Potential. Nano Trends. 2026;14:100203. https:\/\/doi.org\/10.1016\/j.nwnano.2026.100203.","DOI":"10.1016\/j.nwnano.2026.100203"},{"issue":"1","key":"358_CR62","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s12672-024-01151-5","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zheng Y, Zhang J, Xu C, Wu J. Apoptotic signaling pathways in bone metastatic lung cancer: a comprehensive analysis. Discover Oncol. 2024;15(1):310. https:\/\/doi.org\/10.1007\/s12672-024-01151-5.","journal-title":"Discover Oncol"},{"issue":"1","key":"358_CR63","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KT, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target therapy. 2024;9(1):175. https:\/\/doi.org\/10.1038\/s41392-024-01856-7.","journal-title":"Signal Transduct Target therapy"},{"issue":"10","key":"358_CR64","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1080\/17425247.2020.1798401","volume":"17","author":"M Kumar","year":"2020","unstructured":"Kumar M, Jha A, Dr M, Mishra B. Targeted drug nanocrystals for pulmonary delivery: a potential strategy for lung cancer therapy. Expert Opin Drug Deliv. 2020;17(10):1459\u201372. https:\/\/doi.org\/10.1080\/17425247.2020.1798401.","journal-title":"Expert Opin Drug Deliv"},{"key":"358_CR65","doi-asserted-by":"publisher","first-page":"104536","DOI":"10.1016\/j.jddst.2023.104536","volume":"84","author":"A Ali","year":"2023","unstructured":"Ali A, Javed R, Farhangi S, Shah T, Ullah S, ul Ain N, Liu T, Guo Z, Lynch I, Raza F, Zhang P. Metal phenolic networks (MPNs)-based pH-sensitive stimulus responsive nanosystems for drug delivery in tumor microenvironment. J Drug Deliv Sci Technol. 2023;84:104536. https:\/\/doi.org\/10.1016\/j.jddst.2023.104536.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"6","key":"358_CR66","doi-asserted-by":"publisher","first-page":"2001680","DOI":"10.1002\/adhm.202001680","volume":"10","author":"A Brouillard","year":"2021","unstructured":"Brouillard A, Deshpande N, Kulkarni AA. Engineered multifunctional nano-and biological materials for cancer immunotherapy. Adv Healthc Mater. 2021;10(6):2001680. https:\/\/doi.org\/10.1002\/adhm.202001680.","journal-title":"Adv Healthc Mater"},{"issue":"9","key":"358_CR67","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/cbin.11841","volume":"46","author":"S Sargazi","year":"2022","unstructured":"Sargazi S, Arshad R, Ghamari R, Rahdar A, Bakhshi A, Karkan SF, Ajalli N, Bilal M, D\u00edez-Pascual AM. siRNA\u2010based nanotherapeutics as emerging modalities for immune\u2010mediated diseases: A preliminary review. Cell Biol Int. 2022;46(9):1320\u201344. https:\/\/doi.org\/10.1002\/cbin.11841.","journal-title":"Cell Biol Int"},{"key":"358_CR68","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3389\/fchem.2020.00647","volume":"8","author":"M Li","year":"2020","unstructured":"Li M, Zhao G, Su WK, Shuai Q. Enzyme-responsive nanoparticles for anti-tumor drug delivery. Front Chem. 2020;8:647. https:\/\/doi.org\/10.3389\/fchem.2020.00647.","journal-title":"Front Chem"},{"issue":"16","key":"358_CR69","doi-asserted-by":"publisher","first-page":"8651","DOI":"10.3390\/ijms22168651","volume":"22","author":"AG Apilan","year":"2021","unstructured":"Apilan AG, Mothersill C. Targeted and Non-Targeted Mechanisms for Killing Hypoxic Tumour Cells\u2014Are There New Avenues for Treatment? Int J Mol Sci. 2021;22(16):8651. https:\/\/doi.org\/10.3390\/ijms22168651.","journal-title":"Int J Mol Sci"},{"key":"358_CR70","doi-asserted-by":"publisher","unstructured":"Javia A, Bardoliwala D, Patel M, Ligands, and Receptors for Targeted Delivery of Nanoparticles. : Recent UpdatesChallenges. InDrug Delivery with Targeted Nanoparticles. 2021:97\u2013130. https:\/\/doi.org\/10.1201\/9781003164739.","DOI":"10.1201\/9781003164739"},{"issue":"6","key":"358_CR71","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/17425247.2022.2083106","volume":"19","author":"S Mojarad-Jabali","year":"2022","unstructured":"Mojarad-Jabali S, Mahdinloo S, Farshbaf M, Sarfraz M, Fatahi Y, Atyabi F, Valizadeh H. Transferrin receptor-mediated liposomal drug delivery: Recent trends in targeted therapy of cancer. Expert Opin Drug Deliv. 2022;19(6):685\u2013705. https:\/\/doi.org\/10.1080\/17425247.2022.2083106.","journal-title":"Expert Opin Drug Deliv"},{"key":"358_CR72","doi-asserted-by":"publisher","first-page":"972046","DOI":"10.3389\/fphar.2022.972046","volume":"13","author":"A Zanello","year":"2022","unstructured":"Zanello A, Bortolotti M, Maiello S, Bolognesi A, Polito L. Anti-PD-L1 immunoconjugates for cancer therapy: Are available antibodies good carriers for toxic payload delivering? Front Pharmacol. 2022;13:972046. https:\/\/doi.org\/10.3389\/fphar.2022.972046.","journal-title":"Front Pharmacol"},{"issue":"3","key":"358_CR73","first-page":"142","volume":"10","author":"AU Choksi","year":"2022","unstructured":"Choksi AU, Khan AI, Lokeshwar SD, Segal D, Weiss RM, Martin DT. Functionalized nanoparticles targeting biomarkers for prostate cancer imaging and therapy. Am J Clin Experimental Urol. 2022;10(3):142.","journal-title":"Am J Clin Experimental Urol"},{"issue":"6","key":"358_CR74","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.3390\/cancers12061609","volume":"12","author":"C Garc\u00eda-Fern\u00e1ndez","year":"2020","unstructured":"Garc\u00eda-Fern\u00e1ndez C, Fornaguera C, Borr\u00f3s S. Nanomedicine in non-small cell lung cancer: from conventional treatments to immunotherapy. Cancers. 2020;12(6):1609. https:\/\/doi.org\/10.3390\/cancers12061609.","journal-title":"Cancers"},{"issue":"6","key":"358_CR75","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3390\/polym12061397","volume":"12","author":"SS Das","year":"2020","unstructured":"Das SS, Bharadwaj P, Bilal M, Barani M, Rahdar A, Taboada P, Bungau S, Kyzas GZ. Stimuli-responsive polymeric nanocarriers for drug delivery, imaging, and theragnosis. Polymers. 2020;12(6):1397. https:\/\/doi.org\/10.3390\/polym12061397.","journal-title":"Polymers"},{"issue":"22","key":"358_CR76","doi-asserted-by":"publisher","first-page":"9956","DOI":"10.7150\/thno.46089","volume":"10","author":"L Jia","year":"2020","unstructured":"Jia L, Pang M, Fan M, Tan X, Wang Y, Huang M, Liu Y, Wang Q, Zhu Y, Yang X. A pH-responsive Pickering Nanoemulsion for specified spatial delivery of Immune Checkpoint Inhibitor and Chemotherapy agent to Tumors. Theranostics. 2020;10(22):9956. https:\/\/doi.org\/10.7150\/thno.46089.","journal-title":"Theranostics"},{"issue":"32","key":"358_CR77","doi-asserted-by":"publisher","first-page":"6326","DOI":"10.1039\/D1TB00728A","volume":"9","author":"Z He","year":"2021","unstructured":"He Z, Xu Q, Newland B, Foley R, Lara-S\u00e1ez I, Curtin JF, Wang W. Reactive oxygen species (ROS): utilizing injectable antioxidative hydrogels and ROS-producing therapies to manage the double-edged sword. J Mater Chem B. 2021;9(32):6326\u201346. https:\/\/doi.org\/10.1039\/D1TB00728A.","journal-title":"J Mater Chem B"},{"issue":"2","key":"358_CR78","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/17425247.2021.1828339","volume":"18","author":"J Majumder","year":"2021","unstructured":"Majumder J, Minko T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin Drug Deliv. 2021;18(2):205\u201327. https:\/\/doi.org\/10.1080\/17425247.2021.1828339.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"358_CR79","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12951-021-00975-5","volume":"19","author":"Z Wang","year":"2021","unstructured":"Wang Z, Chen L, Ma Y, Li X, Hu A, Wang H, Wang W, Li X, Tian B, Dong J. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal. J Nanobiotechnol. 2021;19(1):243. https:\/\/doi.org\/10.1186\/s12951-021-00975-5.","journal-title":"J Nanobiotechnol"},{"issue":"5","key":"358_CR80","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3390\/pharmaceutics16050636","volume":"16","author":"AB Kuznetsova","year":"2024","unstructured":"Kuznetsova AB, Kolesova EP, Parodi A, Zamyatnin AA Jr, Egorova VS. Reprogramming Tumor-Associated Macrophage Using Nanocarriers: New Perspectives to Halt Cancer Progression. Pharmaceutics. 2024;16(5):636. https:\/\/doi.org\/10.3390\/pharmaceutics16050636.","journal-title":"Pharmaceutics"},{"issue":"Pt A","key":"358_CR81","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jconrel.2016.11.005","volume":"244","author":"Y Xiong","year":"2016","unstructured":"Xiong Y, Zhao Y, Miao L, Lin CM, Huang L. Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer. J Control Release. 2016;244(Pt A):63\u201373. https:\/\/doi.org\/10.1016\/j.jconrel.2016.11.005.","journal-title":"J Control Release"},{"issue":"1","key":"358_CR82","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3892\/ijo.2025.5760","volume":"67","author":"AY Park","year":"2025","unstructured":"Park AY, Kim JH, Lee S, Kim HS, Kim HK, Lee HB, Han W. Impact of PD-L1 upregulation on immune checkpoint inhibitor efficacy in triple-negative breast cancer using a 4T1 murine model. Int J Oncol. 2025;67(1):54. https:\/\/doi.org\/10.3892\/ijo.2025.5760.","journal-title":"Int J Oncol"},{"issue":"4","key":"358_CR83","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1039\/d1nr06577g","volume":"14","author":"PU Atukorale","year":"2022","unstructured":"Atukorale PU, Moon TJ, Bokatch AR, Lusi CF, Routhier JT, Deng VJ, Karathanasis E. Dual agonist immunostimulatory nanoparticles combine with PD1 blockade for curative neoadjuvant immunotherapy of aggressive cancers. Nanoscale. 2022;14(4):1144\u201359. https:\/\/doi.org\/10.1039\/d1nr06577g.","journal-title":"Nanoscale"},{"issue":"21","key":"358_CR84","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.3390\/cells11213434","volume":"11","author":"SS Kim","year":"2022","unstructured":"Kim SS, Harford JB, Moghe M, Doherty C, Chang EH. A Novel P53 Nanomedicine Reduces Immunosuppression and Augments Anti-PD-1 Therapy for Non-Small Cell Lung Cancer in Syngeneic Mouse Models. Cells. 2022;11(21):3434. https:\/\/doi.org\/10.3390\/cells11213434.","journal-title":"Cells"},{"issue":"7","key":"358_CR85","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1007\/s00432-022-04298-2","volume":"149","author":"L Zhang","year":"2023","unstructured":"Zhang L, Xie G, Xiao X, Cheng C. Characterization of PDL1 enhanced siRNA\/albumin liposome for effective therapeutic function in lung cancer. J Cancer Res Clin Oncol. 2023;149(7):3835\u201346. https:\/\/doi.org\/10.1007\/s00432-022-04298-2.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"28","key":"358_CR86","doi-asserted-by":"publisher","first-page":"19540","DOI":"10.1039\/d3ra03099g","volume":"13","author":"P Jiang","year":"2023","unstructured":"Jiang P, Liang B, Zhang Z, Fan B, Zeng L, Zhou Z, Mao Z, Xu Q, Yao W, Shen Q. New insights into nanosystems for non-small-cell lung cancer: diagnosis and treatment. RSC Adv. 2023;13(28):19540\u201364. https:\/\/doi.org\/10.1039\/d3ra03099g.","journal-title":"RSC Adv"},{"key":"358_CR87","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.canlet.2020.05.032","volume":"490","author":"Y Li","year":"2020","unstructured":"Li Y, Jeon J, Park JH. Hypoxia-responsive nanoparticles for tumor-targeted drug delivery. Cancer Lett. 2020;490:31\u201343. https:\/\/doi.org\/10.1016\/j.canlet.2020.05.032.","journal-title":"Cancer Lett"},{"key":"358_CR88","doi-asserted-by":"publisher","unstructured":"Araujo LH, Horn L, Merritt RE, Shilo K, Xu-Welliver M, Carbone DP. Cancer of the lung: Non\u2013small cell lung cancer and small cell lung cancer. InAbeloff\u2019s clinical oncology. 2020:1108\u20131158. https:\/\/doi.org\/10.1016\/B978-0-323-47674-4.00069-4.","DOI":"10.1016\/B978-0-323-47674-4.00069-4"},{"issue":"5","key":"358_CR89","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.3390\/ijms23052847","volume":"23","author":"P Dobosz","year":"2022","unstructured":"Dobosz P, St\u0119pie\u0144 M, Golke A, Dzieci\u0105tkowski T. Challenges of the immunotherapy: perspectives and limitations of the immune checkpoint inhibitor treatment. Int J Mol Sci. 2022;23(5):2847. https:\/\/doi.org\/10.3390\/ijms23052847.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"358_CR90","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1021\/acs.accounts.0c00339","volume":"53","author":"X Han","year":"2020","unstructured":"Han X, Li H, Zhou D, Chen Z, Gu Z. Local and targeted delivery of immune checkpoint blockade therapeutics. Acc Chem Res. 2020;53(11):2521\u201333. https:\/\/doi.org\/10.1021\/acs.accounts.0c00339.","journal-title":"Acc Chem Res"},{"key":"358_CR91","doi-asserted-by":"publisher","first-page":"751209","DOI":"10.3389\/fonc.2021.751209","volume":"11","author":"N Wiest","year":"2021","unstructured":"Wiest N, Majeed U, Seegobin K, Zhao Y, Lou Y, Manochakian R. Role of immune checkpoint inhibitor therapy in advanced EGFR-mutant non-small cell lung cancer. Front Oncol. 2021;11:751209. https:\/\/doi.org\/10.3389\/fonc.2021.751209.","journal-title":"Front Oncol"},{"issue":"25","key":"358_CR92","doi-asserted-by":"publisher","first-page":"7906","DOI":"10.7150\/thno.38425","volume":"9","author":"S Lim","year":"2019","unstructured":"Lim S, Park J, Shim MK, Um W, Yoon HY, Ryu JH, Lim DK, Kim K. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. Theranostics. 2019;9(25):7906. https:\/\/doi.org\/10.7150\/thno.38425.","journal-title":"Theranostics"},{"key":"358_CR93","doi-asserted-by":"publisher","first-page":"728018","DOI":"10.3389\/fonc.2021.728018","volume":"11","author":"KP Fabian","year":"2021","unstructured":"Fabian KP, Wolfson B, Hodge JW. From immunogenic cell death to immunogenic modulation: select chemotherapy regimens induce a spectrum of immune-enhancing activities in the tumor microenvironment. Front Oncol. 2021;11:728018. https:\/\/doi.org\/10.3389\/fonc.2021.728018.","journal-title":"Front Oncol"},{"issue":"14","key":"358_CR94","doi-asserted-by":"publisher","first-page":"7717","DOI":"10.3390\/ijms22147717","volume":"22","author":"G Giordano","year":"2021","unstructured":"Giordano G, Parcesepe P, Bruno G, Piscazzi A, Lizzi V, Remo A, Pancione M, D\u2019Andrea MR, De Santis E, Coppola L, Pietrafesa M. Evidence-based second-line treatment in RAS wild-type\/mutated metastatic colorectal cancer in the precision medicine era. Int J Mol Sci. 2021;22(14):7717. https:\/\/doi.org\/10.3390\/ijms22147717.","journal-title":"Int J Mol Sci"},{"key":"358_CR95","doi-asserted-by":"publisher","first-page":"120407","DOI":"10.1016\/j.biomaterials.2020.120407","volume":"265","author":"D Hu","year":"2021","unstructured":"Hu D, Zhang W, Tang J, Zhou Z, Liu X, Shen Y. Improving safety of cancer immunotherapy via delivery technology. Biomaterials. 2021;265:120407. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120407.","journal-title":"Biomaterials"},{"issue":"1","key":"358_CR96","doi-asserted-by":"publisher","first-page":"e000200","DOI":"10.1136\/jitc-2019-000200","volume":"8","author":"S Qu","year":"2020","unstructured":"Qu S, Worlikar T, Felsted AE, Ganguly A, Beems MV, Hubbard R, Pepple AL, Kevelin AA, Garavaglia H, Dib J, Toma M. Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy. J Immunother Cancer. 2020;8(1):e000200. https:\/\/doi.org\/10.1136\/jitc-2019-000200.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"358_CR97","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1021\/acs.molpharmaceut.1c00856","volume":"19","author":"L Qiao","year":"2022","unstructured":"Qiao L, Yang H, Shao XX, Yin Q, Fu XJ, Wei Q. Research progress on nanoplatforms and nanotherapeutic strategies in treating glioma. Mol Pharm. 2022;19(7):1927\u201351. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00856.","journal-title":"Mol Pharm"},{"issue":"2","key":"358_CR98","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/biomedicines7020036","volume":"7","author":"CR Pangilinan","year":"2019","unstructured":"Pangilinan CR, Lee CH. Salmonella-based targeted cancer therapy: updates on a promising and innovative tumor immunotherapeutic strategy. Biomedicines. 2019;7(2):36. https:\/\/doi.org\/10.3390\/biomedicines7020036.","journal-title":"Biomedicines"},{"issue":"1","key":"358_CR99","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/ijms23010022","volume":"23","author":"KJ Lagos","year":"2021","unstructured":"Lagos KJ, Buzz\u00e1 HH, Bagnato VS, Romero MP. Carbon-based materials in photodynamic and photothermal therapies applied to tumor destruction. Int J Mol Sci. 2021;23(1):22. https:\/\/doi.org\/10.3390\/ijms23010022.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"358_CR100","doi-asserted-by":"publisher","first-page":"2103836","DOI":"10.1002\/advs.202103836","volume":"9","author":"S Peng","year":"2022","unstructured":"Peng S, Xiao F, Chen M, Gao H. Tumor-microenvironment\u2010responsive nanomedicine for enhanced cancer immunotherapy. Adv Sci. 2022;9(1):2103836. https:\/\/doi.org\/10.1002\/advs.202103836.","journal-title":"Adv Sci"},{"key":"358_CR101","doi-asserted-by":"publisher","first-page":"955920","DOI":"10.3389\/fimmu.2022.955920","volume":"13","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Liu X, Liu X, Yu J, Bai X, Wu X, Guo X, Liu Z, Liu X. Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer. Front Immunol. 2022;13:955920. https:\/\/doi.org\/10.3389\/fimmu.2022.955920.","journal-title":"Front Immunol"},{"issue":"2","key":"358_CR102","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3390\/pharmaceutics15020330","volume":"15","author":"J Heuts","year":"2023","unstructured":"Huis in, Heuts J, Ma S, Cruz LJ, Ossendorp FA, Jager MJ. Current challenges and opportunities of photodynamic therapy against cancer. Pharmaceutics. 2023;15(2):330. https:\/\/doi.org\/10.3390\/pharmaceutics15020330.","journal-title":"Pharmaceutics"},{"key":"358_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-1062-7","volume":"18","author":"A Lin","year":"2019","unstructured":"Lin A, Wei T, Meng H, Luo P, Zhang J. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Mol Cancer. 2019;18:1\u20138. https:\/\/doi.org\/10.1186\/s12943-019-1062-7.","journal-title":"Mol Cancer"},{"issue":"10","key":"358_CR104","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1039\/D0CS00718H","volume":"50","author":"Y Xiong","year":"2021","unstructured":"Xiong Y, Xiao C, Li Z, Yang X. Engineering nanomedicine for glutathione depletion-augmented cancer therapy. Chem Soc Rev. 2021;50(10):6013\u201341. https:\/\/doi.org\/10.1039\/D0CS00718H.","journal-title":"Chem Soc Rev"},{"issue":"8","key":"358_CR105","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345\u201356. https:\/\/doi.org\/10.1038\/s41591-021-01450-2.","journal-title":"Nat Med"},{"key":"358_CR106","doi-asserted-by":"publisher","first-page":"602762","DOI":"10.3389\/fonc.2020.602762","volume":"10","author":"L Wu","year":"2020","unstructured":"Wu L, Ke L, Zhang Z, Yu J, Meng X. Development of EGFR TKIs and options to manage resistance of third-generation EGFR TKI osimertinib: conventional ways and immune checkpoint inhibitors. Front Oncol. 2020;10:602762. https:\/\/doi.org\/10.3389\/fonc.2020.602762.","journal-title":"Front Oncol"},{"issue":"1","key":"358_CR107","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41392-023-01642-x","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun L, Liu H, Ye Y, Lei Y, Islam R, Tan S, Tong R, Miao YB, Cai L. Smart nanoparticles for cancer therapy. Signal Transduct Target therapy. 2023;8(1):418. https:\/\/doi.org\/10.1038\/s41392-023-01642-x.","journal-title":"Signal Transduct Target therapy"},{"issue":"52","key":"358_CR108","doi-asserted-by":"publisher","first-page":"38952","DOI":"10.1039\/d4ra07114j","volume":"14","author":"SS Shabnum","year":"2024","unstructured":"Shabnum SS, Siranjeevi R, Raj CK, Saravanan A, Vickram AS, Chopra H, Malik T. Advancements in nanotechnology-driven photodynamic and photothermal therapies: mechanistic insights and synergistic approaches for cancer treatment. RSC Adv. 2024;14(52):38952\u201395. https:\/\/doi.org\/10.1039\/d4ra07114j.","journal-title":"RSC Adv"},{"key":"358_CR109","doi-asserted-by":"publisher","first-page":"103515","DOI":"10.1016\/j.redox.2025.103515","volume":"80","author":"Q Guo","year":"2025","unstructured":"Guo Q, Tang Y, Wang S, Xia X. Applications and enhancement strategies of ROS-based non-invasive therapies in cancer treatment. Redox Biol. 2025;80:103515.","journal-title":"Redox Biol"},{"issue":"1","key":"358_CR110","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12943-025-02357-z","volume":"24","author":"H Sabit","year":"2025","unstructured":"Sabit H, Pawlik TM, Radwan F, Abdel-Hakeem M, Abdel-Ghany S, Wadan AS, Elzawahri M, El-Hashash A, Arneth B. Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery. Mol Cancer. 2025;24(1):160. https:\/\/doi.org\/10.1186\/s12943-025-02357-z.","journal-title":"Mol Cancer"},{"issue":"1","key":"358_CR111","doi-asserted-by":"publisher","first-page":"e1739","DOI":"10.1002\/wnan.1739","volume":"14","author":"CE Boone","year":"2022","unstructured":"Boone CE, Wang L, Gautam A, Newton IG, Steinmetz NF. Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022;14(1):e1739. https:\/\/doi.org\/10.1002\/wnan.1739.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"5","key":"358_CR112","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.xphs.2020.08.027","volume":"110","author":"M Sharpe","year":"2021","unstructured":"Sharpe M, Barry J, Kefalas P. Clinical adoption of advanced therapies: challenges and opportunities. J Pharm Sci. 2021;110(5):1877\u201384. https:\/\/doi.org\/10.1016\/j.xphs.2020.08.027.","journal-title":"J Pharm Sci"},{"issue":"6","key":"358_CR113","doi-asserted-by":"publisher","first-page":"1801002","DOI":"10.1002\/adhm.201801002","volume":"8","author":"N Wang","year":"2019","unstructured":"Wang N, Cheng X, Li N, Wang H, Chen H. Nanocarriers and their loading strategies. Adv Healthc Mater. 2019;8(6):1801002. https:\/\/doi.org\/10.1002\/adhm.201801002.","journal-title":"Adv Healthc Mater"},{"issue":"6","key":"358_CR114","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1039\/C9BM01643K","volume":"8","author":"Q Muhammad","year":"2020","unstructured":"Muhammad Q, Jang Y, Kang SH, Moon J, Kim WJ, Park H. Modulation of immune responses with nanoparticles and reduction of their immunotoxicity. Biomaterials Sci. 2020;8(6):1490\u2013501. https:\/\/doi.org\/10.1039\/C9BM01643K.","journal-title":"Biomaterials Sci"},{"issue":"11","key":"358_CR115","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11095-019-2692-6","volume":"36","author":"M Rawal","year":"2019","unstructured":"Rawal M, Singh A, Amiji MM. Quality-by-design concepts to improve nanotechnology-based drug development. Pharm Res. 2019;36(11):153. https:\/\/doi.org\/10.1007\/s11095-019-2692-6.","journal-title":"Pharm Res"},{"issue":"8","key":"358_CR116","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1039\/D0RE00078G","volume":"5","author":"MO Besenhard","year":"2020","unstructured":"Besenhard MO, LaGrow AP, Famiani S, Pucciarelli M, Lettieri P, Thanh NT, Gavriilidis A. Continuous production of iron oxide nanoparticles via fast and economical high temperature synthesis. Reaction Chem Eng. 2020;5(8):1474\u201383. https:\/\/doi.org\/10.1039\/D0RE00078G.","journal-title":"Reaction Chem Eng"},{"key":"358_CR117","doi-asserted-by":"publisher","unstructured":"Ahmad I, Zafar S, Ahmad S, Saad S, Kawish SM, Agarwal S, Ahmad FJ. Long-Term Toxicity and Regulations for Bioactive-Loaded Nanomedicines. InBiomarkers as Targeted Herbal Drug Discovery. 2021:249\u2013275. https:\/\/doi.org\/10.1201\/9781003045526.","DOI":"10.1201\/9781003045526"},{"key":"358_CR118","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/NSA.S49052","volume":"8","author":"J Ahmad","year":"2015","unstructured":"Ahmad J, Akhter S, Rizwanullah M, Amin S, Rahman M, Ahmad MZ, Rizvi MA, Kamal MA, Ahmad FJ. Nanotechnology-based inhalation treatments for lung cancer: state of the art. Nanotechnol Sci Appl. 2015;8:55\u201366. https:\/\/doi.org\/10.2147\/NSA.S49052.","journal-title":"Nanotechnol Sci Appl"},{"issue":"1","key":"358_CR119","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41565-020-00817-9","volume":"16","author":"W Jiang","year":"2021","unstructured":"Jiang W, Wang Y, Wargo JA, Lang FF, Kim BY. Considerations for designing preclinical cancer immune nanomedicine studies. Nat Nanotechnol. 2021;16(1):6\u201315. https:\/\/doi.org\/10.1038\/s41565-020-00817-9.","journal-title":"Nat Nanotechnol"},{"issue":"3","key":"358_CR120","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.3390\/ijms23031853","volume":"23","author":"M Haider","year":"2022","unstructured":"Haider M, Elsherbeny A, Pittal\u00e0 V, Consoli V, Alghamdi MA, Hussain Z, Khoder G, Greish K. Nanomedicine strategies for management of drug resistance in lung cancer. Int J Mol Sci. 2022;23(3):1853. https:\/\/doi.org\/10.3390\/ijms23031853.","journal-title":"Int J Mol Sci"},{"key":"358_CR121","doi-asserted-by":"publisher","unstructured":"Park SJ. Protein\u2013nanoparticle interaction: corona formation and conformational changes in proteins on nanoparticles. Int J Nanomed. 2020:5783\u2013802. https:\/\/doi.org\/10.2147\/IJN.S254808.","DOI":"10.2147\/IJN.S254808"},{"issue":"1","key":"358_CR122","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1080\/14686996.2019.1627174","volume":"20","author":"M Mohamed","year":"2019","unstructured":"Mohamed M, Abu Lila AS, Shimizu T, Alaaeldin E, Hussein A, Sarhan HA, Szebeni J, Ishida T. PEGylated liposomes: immunological responses. Sci Technol Adv Mater. 2019;20(1):710\u201324. https:\/\/doi.org\/10.1080\/14686996.2019.1627174.","journal-title":"Sci Technol Adv Mater"},{"issue":"2","key":"358_CR123","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/jpm11020124","volume":"11","author":"D Huang","year":"2021","unstructured":"Huang D, Sun L, Huang L, Chen Y. Nanodrug delivery systems modulate tumor vessels to increase the enhanced permeability and retention effect. J personalized Med. 2021;11(2):124. https:\/\/doi.org\/10.3390\/jpm11020124.","journal-title":"J personalized Med"},{"issue":"8","key":"358_CR124","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1016\/j.apsb.2022.02.023","volume":"12","author":"Y Zeng","year":"2022","unstructured":"Zeng Y, Li S, Zhang S, Wang L, Yuan H, Hu F. Cell membrane coated-nanoparticles for cancer immunotherapy. Acta Pharm Sinica B. 2022;12(8):3233\u201354. https:\/\/doi.org\/10.1016\/j.apsb.2022.02.023.","journal-title":"Acta Pharm Sinica B"},{"issue":"11","key":"358_CR125","doi-asserted-by":"publisher","first-page":"e22900","DOI":"10.1002\/jbt.22900","volume":"35","author":"M Najafi","year":"2021","unstructured":"Najafi M, Majidpoor J, Toolee H, Mortezaee K. The current knowledge concerning solid cancer and therapy. J Biochem Mol Toxicol. 2021;35(11):e22900. https:\/\/doi.org\/10.1002\/jbt.22900.","journal-title":"J Biochem Mol Toxicol"},{"issue":"36","key":"358_CR126","doi-asserted-by":"publisher","first-page":"7461","DOI":"10.2174\/0929867328666210406115529","volume":"28","author":"I Cs\u00f3ka","year":"2021","unstructured":"Cs\u00f3ka I, Ismail R, J\u00f3j\u00e1rt-Laczkovich O, Pallagi E. Regulatory considerations, challenges and risk-based approach in nanomedicine development. Curr Med Chem. 2021;28(36):7461\u201376. https:\/\/doi.org\/10.2174\/0929867328666210406115529.","journal-title":"Curr Med Chem"},{"key":"358_CR127","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.envres.2019.02.003","volume":"172","author":"N Prajitha","year":"2019","unstructured":"Prajitha N, Athira SS, Mohanan PV. Bio-interactions and risks of engineered nanoparticles. Environ Res. 2019;172:98\u2013108. https:\/\/doi.org\/10.1016\/j.envres.2019.02.003.","journal-title":"Environ Res"},{"key":"358_CR128","doi-asserted-by":"publisher","first-page":"101184","DOI":"10.1016\/j.nantod.2021.101184","volume":"39","author":"O Bondarenko","year":"2021","unstructured":"Bondarenko O, Mortimer M, Kahru A, Feliu N, Javed I, Kakinen A, Lin S, Xia T, Song Y, Davis TP, Lynch I. Nanotoxicology and nanomedicine: The Yin and Yang of nano-bio interactions for the new decade. Nano Today. 2021;39:101184. https:\/\/doi.org\/10.1016\/j.nantod.2021.101184.","journal-title":"Nano Today"},{"key":"358_CR129","doi-asserted-by":"publisher","first-page":"114318","DOI":"10.1016\/j.nantod.2021.101184","volume":"186","author":"J Liu","year":"2022","unstructured":"Liu J, Guo M, Chen C. Nano-bio interactions: A major principle in the dynamic biological processes of nano-assemblies. Adv Drug Deliv Rev. 2022;186:114318. https:\/\/doi.org\/10.1016\/j.nantod.2021.101184.","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"358_CR130","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.3390\/nano10101911","volume":"10","author":"Y Kohl","year":"2020","unstructured":"Kohl Y, Rund\u00e9n-Pran E, Mariussen E, Hesler M, El Yamani N, Longhin EM, Dusinska M. Genotoxicity of nanomaterials: advanced in vitro models and high throughput methods for human hazard assessment\u2014a review. Nanomaterials. 2020;10(10):1911. https:\/\/doi.org\/10.3390\/nano10101911.","journal-title":"Nanomaterials"},{"key":"358_CR131","doi-asserted-by":"publisher","unstructured":"Sucheta, Britya NV, Jha M, Yadav R, Chahal K, Nagori K, Tiwari M, Singh MK, Sharma V. Clinical and Regulatory Consideration for Nanobiomaterials. InBiomaterial-Inspired Nanomedicines for Targeted Therapies. 2024:451\u2013476. https:\/\/doi.org\/10.1007\/978-981-97-3925-7_17.","DOI":"10.1007\/978-981-97-3925-7_17"},{"key":"358_CR132","doi-asserted-by":"publisher","unstructured":"Jain AK, Thareja S. In vitro and in vivo characterization of pharmaceutical nanocarriers used for drug delivery. Artificial cells, nanomedicine, and biotechnology. 2019;47(1):524\u201339. https:\/\/doi.org\/10.1080\/21691401.2018.1561457.","DOI":"10.1080\/21691401.2018.1561457"},{"key":"358_CR133","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00280-021-04235-z","volume":"87","author":"WW Ma","year":"2021","unstructured":"Ma WW, Zhu M, Lam ET, Diamond JR, Dy GK, Fisher GA, Goff LW, Alberts S, Bui LA, Sanghal A, Kothekar M. A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers. Cancer Chemother Pharmacol. 2021;87:779\u201388. https:\/\/doi.org\/10.1007\/s00280-021-04235-z.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"358_CR134","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","volume":"5","author":"LA Emens","year":"2019","unstructured":"Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019;5(1):74\u201382. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4224.","journal-title":"JAMA Oncol"},{"issue":"5","key":"358_CR135","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.drudis.2021.12.021","volume":"27","author":"S Wang","year":"2022","unstructured":"Wang S, Yang Q, Deng L, Lei Q, Yang Y, Ma P, Men Y, Yung BC, Lee RJ, Zhang M, Li N. An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020. Drug Discovery Today. 2022;27(5):1236\u201350. https:\/\/doi.org\/10.1016\/j.drudis.2021.12.021.","journal-title":"Drug Discovery Today"},{"issue":"6","key":"358_CR136","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s41588-020-0630-5","volume":"52","author":"A Jim\u00e9nez-S\u00e1nchez","year":"2020","unstructured":"Jim\u00e9nez-S\u00e1nchez A, Cybulska P, Mager KL, Koplev S, Cast O, Couturier DL, Memon D, Selenica P, Nikolovski I, Mazaheri Y, Bykov Y. Unraveling tumor\u2013immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nat Genet. 2020;52(6):582\u201393. https:\/\/doi.org\/10.1038\/s41588-020-0630-5.","journal-title":"Nat Genet"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00358-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00358-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00358-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T23:02:58Z","timestamp":1782687778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-026-00358-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":136,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["358"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00358-7","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}